following a full submission:
dupilumab (Dupixent®) is not recommended for use within NHSScotland.
Indication under review: in adults as add-on maintenance treatment for uncontrolled chronic obstructive pulmonary disease (COPD) characterised by raised blood eosinophils on a combination of an inhaled corticosteroid (ICS), a long-acting beta2-agonist (LABA), and a long-acting muscarinic antagonist (LAMA), or on a combination of a LABA and a LAMA if ICS is not appropriate.
In two phase III studies, the addition of dupilumab compared with placebo to triple inhaler therapy significantly reduced the annualised rate of moderate or severe COPD exacerbations in patients with uncontrolled COPD with raised blood eosinophils.
The submitting company did not present a sufficiently robust economic analysis to gain acceptance by SMC.
Medicine details
- Medicine name:
- dupilumab (Dupixent)
- SMC ID:
- SMC2801
- Indication:
In adults as add-on maintenance treatment for uncontrolled chronic obstructive pulmonary disease (COPD) characterised by raised blood eosinophils on a combination of an inhaled corticosteroid (ICS), a long-acting beta2-agonist (LABA), and a long-acting muscarinic antagonist (LAMA), or on a combination of a LABA and a LAMA if ICS is not appropriate.
- Pharmaceutical company
- Sanofi
- BNF chapter
- Respiratory system
- Submission type
- Full
- Status
- Not recommended
- Date advice published
- 11 August 2025